Status:
UNKNOWN
De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations
Lead Sponsor:
Fudan University
Conditions:
Oropharyngeal Carcinoma
De-escalation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and showed pr...
Eligibility Criteria
Inclusion
- Histological diagnosis of squamous cell carcinoma of oropharynx with IHC p16 positive or PCR HPV16 positive
- T1-2/N1-3M0（except T1N1M0 and single LN\<3cm）or T3-4N0-3M0 according to UICC/AJCC 8th staging system
- Age ≥18
- No prior anti-tumor treatment
- Karnofsky Performance Score (KPS)≥70
- Adequate blood supply
- Informed consent obtained
Exclusion
- cannot take contrast-MRI imaging
- Pregnant
- Combined with other malignant tumor (except basal cell carcinoma of skin)
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT04012502
Start Date
July 1 2019
End Date
December 31 2020
Last Update
July 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan Universtiy Shanghai Cancer Centre
Shanghai, Shanghai Municipality, China, 200032